** Shares of drugmaker Jazz Pharmaceuticals JAZZ.O fall 2% to $232.01 premarket

** Co says Zepzelca failed to help patients with relapsed small cell lung cancer, an aggressive form of lung cancer that spreads quickly, live longer in a late-stage study

** Says study tested Zepzelca alone and with chemotherapy irinotecan vs standard treatment in patients whose cancer had returned

** Co's Zepzelca alone showed median survival of 8.7 months vs 10.7 months for standard care; combo arm 10.9 months, co says

** Says differences were not statistically meaningful; no new safety issues seen

** Co says results will not impact 2026 forecast; to discuss data with FDA

** As of last close, LIXT stock up ~39% YTD